MX2022002581A - Compuestos de benzimidazol como inhibidores de c-kit. - Google Patents
Compuestos de benzimidazol como inhibidores de c-kit.Info
- Publication number
- MX2022002581A MX2022002581A MX2022002581A MX2022002581A MX2022002581A MX 2022002581 A MX2022002581 A MX 2022002581A MX 2022002581 A MX2022002581 A MX 2022002581A MX 2022002581 A MX2022002581 A MX 2022002581A MX 2022002581 A MX2022002581 A MX 2022002581A
- Authority
- MX
- Mexico
- Prior art keywords
- kit inhibitors
- benzimidazole compounds
- kit
- inhibitors
- benzimidazole
- Prior art date
Links
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title abstract 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a inhibidores de c-Kit útiles en el tratamiento de cánceres y otras enfermedades mediadas por serina-treonina quinasa, que tienen la Fórmula: (ver Fórmula) donde A, L, R1, R2, R3, y n se describen en la presente descripción.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434839P | 2016-12-15 | 2016-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002581A true MX2022002581A (es) | 2022-03-22 |
Family
ID=60888754
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007080A MX390348B (es) | 2016-12-15 | 2017-12-14 | Compuestos de benzimidazol como inhibidores de c-kit |
| MX2022002581A MX2022002581A (es) | 2016-12-15 | 2019-06-14 | Compuestos de benzimidazol como inhibidores de c-kit. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007080A MX390348B (es) | 2016-12-15 | 2017-12-14 | Compuestos de benzimidazol como inhibidores de c-kit |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11117883B2 (es) |
| EP (1) | EP3555066A1 (es) |
| JP (2) | JP7158383B2 (es) |
| KR (1) | KR20190092538A (es) |
| CN (3) | CN116283910A (es) |
| AU (3) | AU2017376629B2 (es) |
| BR (1) | BR112019012224A2 (es) |
| CA (1) | CA3047107A1 (es) |
| EA (1) | EA201991197A1 (es) |
| IL (3) | IL287517B2 (es) |
| MA (1) | MA53150A (es) |
| MX (2) | MX390348B (es) |
| WO (1) | WO2018112140A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116283910A (zh) * | 2016-12-15 | 2023-06-23 | 阿瑞雅德制药公司 | 作为c-kit抑制剂的苯并咪唑化合物 |
| CN109320503B (zh) * | 2018-12-10 | 2022-07-01 | 怀化学院 | 苯并咪唑炔胺类化合物的无金属一锅合成方法 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR20250167002A (ko) | 2023-04-11 | 2025-11-28 | 길리애드 사이언시즈, 인코포레이티드 | Kras 조절 화합물 |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| AU2004268949A1 (en) * | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl C-kit inhibitors |
| JP2008521903A (ja) * | 2004-12-01 | 2008-06-26 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Ｎ置換されたベンズイミダゾリルＣ−ｋｉｔ阻害剤及びコンビナトリアルベンゾイミダゾールライブラリー |
| UA94055C2 (en) * | 2005-08-30 | 2011-04-11 | Новартис Аг | Substituted benzimidazoles and methods of preparation |
| WO2011053938A1 (en) * | 2009-10-30 | 2011-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
| NZ599041A (en) * | 2009-11-13 | 2014-05-30 | Genosco | Kinase inhibitors |
| BR112013024171A2 (pt) * | 2011-04-07 | 2016-12-13 | Ariad Pharma Inc | método para o tratamento e prevenção de uma condição neurodegenerativa |
| CN103664787B (zh) * | 2012-09-17 | 2015-09-09 | 南京圣和药业股份有限公司 | 炔杂芳环化合物及其应用 |
| CA3022250A1 (en) * | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| GB2522226A (en) * | 2014-01-17 | 2015-07-22 | Agency Science Tech & Res | Heteroaryl alkyne derivatives and uses thereof |
| CN116283910A (zh) * | 2016-12-15 | 2023-06-23 | 阿瑞雅德制药公司 | 作为c-kit抑制剂的苯并咪唑化合物 |
-
2017
- 2017-12-14 CN CN202211737801.7A patent/CN116283910A/zh active Pending
- 2017-12-14 EP EP17822994.4A patent/EP3555066A1/en not_active Withdrawn
- 2017-12-14 US US16/469,535 patent/US11117883B2/en not_active Expired - Fee Related
- 2017-12-14 BR BR112019012224-9A patent/BR112019012224A2/pt not_active Application Discontinuation
- 2017-12-14 CA CA3047107A patent/CA3047107A1/en active Pending
- 2017-12-14 AU AU2017376629A patent/AU2017376629B2/en not_active Ceased
- 2017-12-14 IL IL287517A patent/IL287517B2/en unknown
- 2017-12-14 WO PCT/US2017/066299 patent/WO2018112140A1/en not_active Ceased
- 2017-12-14 KR KR1020197020159A patent/KR20190092538A/ko not_active Abandoned
- 2017-12-14 MA MA053150A patent/MA53150A/fr unknown
- 2017-12-14 IL IL314209A patent/IL314209A/en unknown
- 2017-12-14 CN CN201780085539.3A patent/CN110291081B/zh not_active Expired - Fee Related
- 2017-12-14 MX MX2019007080A patent/MX390348B/es unknown
- 2017-12-14 EA EA201991197A patent/EA201991197A1/ru unknown
- 2017-12-14 CN CN202211731994.5A patent/CN116178343A/zh active Pending
- 2017-12-14 JP JP2019531992A patent/JP7158383B2/ja active Active
-
2019
- 2019-06-12 IL IL267260A patent/IL267260B2/en unknown
- 2019-06-14 MX MX2022002581A patent/MX2022002581A/es unknown
-
2021
- 2021-08-12 US US17/400,820 patent/US20220064144A1/en not_active Abandoned
-
2022
- 2022-02-18 AU AU2022201082A patent/AU2022201082B2/en not_active Ceased
- 2022-10-11 JP JP2022163367A patent/JP2022185110A/ja active Pending
-
2024
- 2024-02-01 AU AU2024200624A patent/AU2024200624A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL287517B1 (en) | 2024-08-01 |
| WO2018112140A1 (en) | 2018-06-21 |
| JP2022185110A (ja) | 2022-12-13 |
| CN110291081B (zh) | 2023-01-31 |
| JP2020503299A (ja) | 2020-01-30 |
| EP3555066A1 (en) | 2019-10-23 |
| CN116178343A (zh) | 2023-05-30 |
| IL267260B (en) | 2022-10-01 |
| IL267260B2 (en) | 2023-02-01 |
| AU2022201082A1 (en) | 2022-03-10 |
| AU2022201082B2 (en) | 2023-11-02 |
| CN116283910A (zh) | 2023-06-23 |
| MX390348B (es) | 2025-03-20 |
| MA53150A (fr) | 2021-05-26 |
| AU2017376629A1 (en) | 2019-07-04 |
| US20220064144A1 (en) | 2022-03-03 |
| IL267260A (en) | 2019-08-29 |
| CA3047107A1 (en) | 2018-06-21 |
| JP7158383B2 (ja) | 2022-10-21 |
| EA201991197A1 (ru) | 2020-01-13 |
| AU2017376629B2 (en) | 2021-11-25 |
| IL314209A (en) | 2024-09-01 |
| MX2019007080A (es) | 2019-10-15 |
| AU2024200624A1 (en) | 2024-02-22 |
| US20200039958A1 (en) | 2020-02-06 |
| KR20190092538A (ko) | 2019-08-07 |
| IL287517B2 (en) | 2024-12-01 |
| US11117883B2 (en) | 2021-09-14 |
| IL287517A (en) | 2021-12-01 |
| BR112019012224A2 (pt) | 2019-11-05 |
| CN110291081A (zh) | 2019-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002581A (es) | Compuestos de benzimidazol como inhibidores de c-kit. | |
| MX2022002579A (es) | Compuestos de aminotiazol como inhibidores de c- kit. | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| MD4650B1 (ro) | Derivaţi de chinazolină utilizaţi în tratamentul HIV | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| PH12017500408A1 (en) | Heteroaryl compunds as btk inhibitors and uses thereof | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| MX382927B (es) | Compuestos de benzolactama como inhibidores de la proteína cinasa. | |
| MX2017012613A (es) | Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm. | |
| PH12015502248B1 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
| MX2017003930A (es) | Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank. | |
| PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| CO2017004784A2 (es) | Isómeros de ácido-1-[(3-cloro-2-fluoro-fenil)metil]-4-[[3-fluoro-6-[(5-metil-1h-pirazol-3-il)amino]-2-piridil]metil]-2-metil-piperidin-4-carboxílico como inhibidores de la cinasa aurora a | |
| MX2018008362A (es) | Derivados de quinolin-2-ona. | |
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
| MX376090B (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas. | |
| NZ747313A (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
| MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
| PH12015502746A1 (en) | Prodrug derivatives of substituted triazolopyridines | |
| PH12017501063A1 (en) | Compounds for the treatment of cancer | |
| TR201908334T4 (tr) | Selektif PI3K delta inhibitörleri. |